Pacira BioSciences
PCRX
183 hedge funds and large institutions have $1.38B invested in Pacira BioSciences in 2016 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 77 increasing their positions, 40 reducing their positions, and 41 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 40
2% more funds holding
Funds holding: 180 → 183 (+3)
10% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 41
40% less capital invested
Capital invested by funds: $2.29B → $1.38B (-$910M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
59% less call options, than puts
Call options by funds: $5.63M | Put options by funds: $13.7M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.9M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$31.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$26.4M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$23.6M |
| 5 |
Millennium Management
New York
|
+$16.6M |
Top Sellers
| 1 |
VAM
Visium Asset Management
New York
|
-$119M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$85.3M |
| 3 |
FAM
Fred Alger Management
New York
|
-$81.5M |
| 4 |
Jennison Associates
New York
|
-$50.5M |
| 5 |
CCI
Columbus Circle Investors
|
-$40.5M |
PCRX Hedge Fund Activity: Q2 2016 in Review
183 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2016, worth a combined $1.38B — down 40% from $2.29B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new PCRX positions and 41 closed out — a net gain of 4 holders — while 77 added to existing stakes and 40 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $43.9M. The largest seller was Visium Asset Management, exiting entirely with an estimated $119M sold.
- 183 institutional investors held Pacira BioSciences (PCRX) as of Q2 2016, up from 180 in Q1 2016.
- Funds reported $1.38B of Pacira BioSciences stock for Q2 2016, down 40% quarter-over-quarter.
- 45 funds opened new Pacira BioSciences positions in Q2 2016 and 41 closed out, a net change of +4 holders.
- The largest Pacira BioSciences buyer in Q2 2016 was Fidelity Investments, an estimated $43.9M added.
- The largest Pacira BioSciences seller in Q2 2016 was Visium Asset Management, an estimated $119M sold.
Based on aggregated 13F filings for Q2 2016.